DNA Immunization with the Gene Encoding P4 Nuclease of Leishmania amazonensis Protects Mice against Cutaneous Leishmaniasis

Infection and Immunity

Volumn 71, Issue 11, 2003, Pages 6270-6278

  Campbell, Kimberly ^a   Diao, Hong ^a   Ji, Jiaxiang ^a   Soong, Lynn ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; HEAT SHOCK PROTEIN 70; IMMUNOGLOBULIN G1; INTERLEUKIN 12; NUCLEASE; NUCLEASE P4; PARASITE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY BURDEN; CLINICAL FEATURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GENETIC VARIABILITY; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION PREVENTION; LEISHMANIA; MOLECULAR CLONING; MOUSE; MOUSE STRAIN; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROMASTIGOTE; PROTECTION; PROTEIN BLOOD LEVEL; PROTEIN PURIFICATION; PROTOZOAL GENETICS; PROVOCATION TEST; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN LEISHMANIASIS; SPECIES DIFFERENCE; TECHNIQUE; TH1 CELL; WOUND HEALING;

ANIMALS; ANTIBODIES, PROTOZOAN; BASE SEQUENCE; CYTOKINES; FEMALE; HSP70 HEAT-SHOCK PROTEINS; IMMUNIZATION; IMMUNOGLOBULIN G; INTERLEUKIN-12; LEISHMANIA MEXICANA; LEISHMANIASIS, CUTANEOUS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; VACCINES, DNA;

EID: 0242286560     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.71.11.6270-6278.2003     Document Type: Article

References (66)

1. Aebischer, T., M. Wolfram, S. I. Patzer, T. Ilg, M. Wiese, and P. Overath. 2000. Subunit vaccination of mice against New World cutaneous leishmaniasis: comparison of three proteins expressed in amastigotes and six adjuvants. Infect. Immun. 68:1328-1336.
2. Afonso, L. C., and P. Scott. 1993. Immune responses associated with susceptibility of C57BL/10 mice to Leishmania amazonensis. Infect. Immun. 61:2952-2959.
3. Armijos, R. X., M. M. Weigel, H. Aviles, R. Maldonado, and J. Racines. 1998. Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: safety, immunogenicity, and efficacy during the first 12 months of follow-up. J. Infect. Dis. 177:1352-1357.
4. Barry, M. A., and S. A. Johnston. 1997. Biological features of genetic immunization. Vaccine 15:788-791.
5. Beyrodt, C. G., A. R. Pinto, E. Freymuller, and C. L. Barbieri. 1997. Characterization of an antigen from Leishmania amazonensis amastigotes able to elicit protective responses in a murine model. Infect. Immun. 65:2052-2059.
6. Campos-Neto, A., J. R. Webb, K. Greeson, R. N. Coler, Y. A. Skeiky, and S. G. Reed. 2002. Vaccination with plasmid DNA encoding TSA/LmST11 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice. Infect. Immun. 70:2828-2836.
7. Chatelain, R., K. Varkila, and R. L. Coffman. 1992. IL-4 induces a Th2 response in Leishmania major-infected mice. J. Immunol. 148:1182-1187.
8. Chopra, U., H. Vohra, S. Chhibber, N. K. Ganguly, and S. Sharma. 1997. TH1 pattern of cytokine secretion by splenic cells from pyelonephritic mice after in-vitro stimulation with HSP-65 of Escherichia coli. J. Med. Microbiol. 46:139-144.
9. Christensen, C. B., L. Jorgensen, A. T. Jensen, S. Gasim, M. Chen, A. Kharazmi, T. G. Theander, and K. Andresen. 2000. Molecular characterization of a Leishmania donovani cDNA clone with similarity to human 20S proteasome a-type subunit. Biochim. Biophys. Acta 1500:77-87.
10. Coler, R. N., Y. A. Skeiky, K. Bernards, K. Greeson, D. Carter, C. D. Cornellison, F. Modabber, A. Campos-Neto, and S. G. Reed. 2002. Immunization with a polyprotein vaccine consisting of the T-cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis. Infect. Immun. 70:4215-4225.
11. Colmenares, M., S. L. Constant, P. E. Kima, and D. McMahon-Pratt. 2002. Leishmania pifanoi pathogenesis: selective lack of a local cutaneous response in the absence of circulating antibody. Infect. Immun. 70:6597-6605.
12. + T-cell-mediated responses in vaccine-induced immunity against Leishmania amazonensis infection. Infect. Immun. 71:3172-3182.
13. Corradin, S. B., Y. Buchmuller-Rouiller, and J. Mauel. 1991. Phagocytosis enhances murine macrophage activation by interferon-gamma and tumor necrosis factor-alpha. Eur. J. Immunol. 21:2553-2558.
14. Corradin, S. B., Y. Buchmuller-Rouiller, J. Smith, L. Suardet, and J. Mauel. 1993. Transforming growth factor beta 1 regulation of macrophage activation depends on the triggering stimulus. J. Leukoc. Biol. 54:423-429.
15. Corradin, S. B., and J. Mauel. 1991. Phagocytosis of Leishmania enhances macrophage activation by IFN-gamma and lipopolysaccharide. J. Immunol. 146:279-285.
16. Courret, N., E. Prina, E. Mougneau, E. M. Saraiva, D. L. Sacks, N. Glaichenhaus, and J. C. Antoine. 1999. Presentation of the Leishmania antigen LACK by infected macrophages is dependent upon the virulence of the phagocytosed parasites. Eur. J. Immunol. 29:762-773.
17. Coutinho, S. G., M. P. Oliveira, A. M. Da-Cruz, P. M. De Luca, S. C. Mendonca, A. L. Bertho, L. Soong, and D. McMahon-Pratt. 1996. T-cell responsiveness of American cutaneous leishmaniasis patients to purified Leishmania pifanoi amastigote antigens and Leishmania braziliensis promastigote antigens: immunologic patterns associated with cure. Exp. Parasitol. 84:144-155.
18. De Luca, P. M., W. Mayrink, C. R. Alves, S. G. Coutinho, M. P. Oliveira, A. L. Bertho, V. P. Toledo, C. A. Costa, O. Genaro, and S. C. Mendonca. 1999. Evaluation of the stability and immunogenicity of autoclaved and nonautoclaved preparations of a vaccine against American tegumentary leishmaniasis. Vaccine 17:1179-1185.
19. Dumonteil, E., F. Andrade-Narvarez, J. Escobedo-Ortegon, M. J. Ramirez-Sierra, G. Valencia-Pacheco, A. Flores-Serrano, S. Canto-Lara, and A. Arjona-Torres. 2000. Comparative study of DNA vaccines encoding various antigens against Leishmania mexicana. Dev. Biol. (Basel) 104:135-141.
20. Dumonteil, E., R. S. Maria Jesus, E. O. Javier, and G. M. Maria del Rosario. 2003. DNA vaccines induce partial protection against Leishmania mexicana. Vaccine 21:2170-2177.
21. Echeverria, P., G. Dran, G. Pereda, A. I. Rico, J. M. Requena, C. Alonso, E. Guarnera, and S. O. Angel. 2001. Analysis of the adjuvant effect of recombinant Leishmania infantum Hsp83 protein as a tool for vaccination. Immunol. Lett. 76:107-110.
22. Fragaki, K., I. Suffia, B. Ferrua, D. Rousseau, Y. Le Fichoux, and J. Kubar. 2001. Immunisation with DNA encoding Leishmania infantum protein papLe22 decreases the frequency of parasitemic episodes in infected hamsters. Vaccine 19:1701-1709.
23. Green, S. J., R. M. Crawford, J. T. Hockmeyer, M. S. Meltzer, and C. A. Nacy. 1990. Leishmania major amastigotes initiate the L-arginine-dependent killing mechanism in IFN-gamma-stimulated macrophages by induction of tumor necrosis factor-alpha. J. Immunol. 145:4290-4297.
24. Guirges, S. Y. 1971. Natural and experimental re-infection of man with Oriental sore. Ann. Trop. Med. Parasitol. 65:197-205.
25. Gurunathan, S., C. Prussin, D. L. Sacks, and R. A. Seder. 1998. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nat. Med. 4:1409-1415.
26. Gurunathan, S., D. L. Sacks, D. R. Brown, S. L. Reiner, H. Charest, N. Glaichenhaus, and R. A. Seder. 1997. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J. Exp. Med. 186:1137-1147.
27. Gurunathan, S., C. Y. Wu, B. L. Freidag, and R. A. Seder. 2000. DNA vaccines: a key for inducing long-term cellular immunity. Curr. Opin. Immunol. 12:442-447.
28. Haberer, J. E., A. M. Da-Cruz, L. Soong, M. P. Oliveira-Neto, L. Rivas, D. McMahon-Pratt, and S. G. Coutinho. 1998. Leishmania pifanoi amastigote antigen P-4: epitopes involved in T-cell responsiveness in human cutaneous leishmaniasis. Infect. Immun. 66:3100-3105.
29. Heinzel, F. P., M. D. Sadick, S. S. Mutha, and R. M. Locksley. 1991. Production of interferon gamma, interleukin 2, interleukin 4, and interleukin 10 by CD4+ lymphocytes in vivo during healing and progressive murine leishmaniasis. Proc. Natl. Acad. Sci. 88:7011-7015.
30. Hodgkinson, V. H., L. Soong, S. M. Duboise, and D. McMahon-Pratt. 1996. Leishmania amazonensis: cultivation and characterization of axenic amastigote-like organisms. Exp. Parasitol. 83:94-105.
31. Jensen, A. T., J. Curtis, J. Montgomery, E. Handman, and T. G. Theander. 2001. Molecular and immunological characterisation of the glucose regulated protein 78 of Leishmania donovani. Biochim. Biophys. Acta 1549:73-87.
32. Ji, J., J. Sun, H. Qi, and L. Soong. 2002. Analysis of T helper cell responses during infection with Leishmania amazonensis. Am. J. Trop. Med. Hyg. 66:338-345.
33. Ji, J., J. Sun, and L. Soong. 2003. Impaired expression of inflammatory cytokines and chemokines at early stages of infection with Leishmania amazonensis. Infect. Immun. 71:4278-4288.
34. Kar, S., L. Soong, M. Colmenares, K. Goldsmith-Pestana, and D. McMahon-Pratt. 2000. The immunologically protective P-4 antigen of Leishmania amastigotes. A developmentally regulated single strand-specific nuclease associated with the endoplasmic reticulum. J. Biol. Chem. 275:37789-37797.
35. Katae, M., Y. Miyahira, K. Takeda, H. Matsuda, H. Yagita, K. Okumura, T. Takeuchi, T. Kamiyama, A. Ohwada, Y. Fukuchi, and T. Aoki. 2002. Coadministration of an interleukin-12 gene and a Trypanosoma cruzi gene improves vaccine efficacy. Infect. Immun. 70:4833-4840.
36. Khalil, E. A., A. M. El Hassan, E. E. Zijlstra, M. M. Mukhtar, H. W. Ghalib, B. Musa, M. E. Ibrahim, A. A. Kamil, M. Elsheikh, A. Babiker, and F. Modabber. 2000. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan. Lancet 356:1565-1569.
37. Khaskhely, N. M., M. Maruno, A. Takamiyagi, H. Uezato, K. M. Kasem, A. Hosokawa, K. Kariya, Y. Hashiguchi, E. A. Landires, and S. Nonaka. 2001. Pre-exposure with low-dose UVA suppresses lesion development and enhances Th1 responses in BALB/c mice infected with Leishmania (Leishmania) amazonensis. J. Derm. Sci. 26:217-232.
38. Kima, P. E., S. L. Constant, L. Hannum, M. Colmenares, K. S. Lee, A. M. Haberman, M. J. Shlomchik, and D. McMahon-Pratt. 2000. Internalization of Leishmania mexicana complex amastigotes via the Fc receptor is required to sustain infection in murine cutaneous leishmaniasis. J. Exp. Med. 191:1063-1068.
39. Locksley, R. M., and J. A. Louis. 1992. Immunology of leishmaniasis. Curr. Opin. Immunol. 4:413-418.
40. Love, D. C., M. Mentink Kane, and D. M. Mosser. 1998. Leishmania amazonensis: the phagocytosis of amastigotes by macrophages. Exp. Parasitol. 88:161-171.
41. Lowrie, D. B., R. E. Tascon, V. L. Bonato, V. M. Lima, L. H. Faccioli, E. Stavropoulos, M. J. Colston, R. G. Hewinson, K. Moelling, and C. L. Silva. 1999. Therapy of tuberculosis in mice by DNA vaccination. Nature 400:269-271.
42. Marzochi, K. B., M. A. Marzochi, A. F. Silva, N. Grativol, R. Duarte, E. M. Confort, and F. Modabber. 1998. Phase 1 study of an inactivated vaccine against American tegumentary leishmaniasis in normal volunteers in Brazil. Mem. Inst. Oswaldo Cruz 93:205-212.
43. Mattner, F., J. Magram, J. Ferrante, P. Launois, K. Di Padova, R. Behin, M. K. Gately, J. A. Louis, and G. Alber. 1996. Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response. Eur. J. Immunol. 26:1553-1559.
44. Melby, P. C., J. Yang, W. Zhao, L. E. Perez, and J. Cheng. 2001. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect. Immun. 69:4719-4725.
45. Mendez, S., S. Gurunathan, S. Kamhawi, Y. Belkaid, M. A. Moga, Y. A. Skeiky, A. Campos-Neto, S. Reed, R. A. Seder, and D. Sacks. 2001. The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated with low-dose, intradermal challenge. J. Immunol. 166:5122-5128.
46. Modabber, F. 1995. Vaccines against leishmaniasis. Ann. Trop. Med. Parasitol. 89(Suppl. 1):83-88.
47. Momeni, A. Z., T. Jalayer, M. Emamjomeh, A. Khamesipour, F. Zicker, R. L. Ghassemi, Y. Dowlati, I. Sharifi, M. Aminjavaheri, A. Shafiei, M. H. Alimohammadian, R. Hashemi-Fesharki, K. Nasseri, T. Godal, P. G. Smith, and F. Modabber. 1999. A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran. Vaccine 17:466-472.
48. Moore, A. C., W. P. Kong, B. K. Chakrabarti, and G. J. Nabel. 2002. Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice. J. Virol. 76:243-250.
49. Noormohammadi, A. H., H. Hochrein, J. M. Curtis, T. M. Baldwin, and E. Handman. 2001. Paradoxical effects of IL-12 in leishmaniasis in the presence and absence of vaccinating antigen. Vaccine 19:4043-4052.
50. Pan, A. A., and D. McMahon-Pratt. 1988. Monoclonal antibodies specific for the amastigote stage of Leishmania pifanoi. 1. Characterization of antigens associated with stage- and species-specific determinants. J. Immunol. 140:2406-2414.
51. Rafati, S., A. H. Salmanian, T. Taheri, M. Vafa, and N. Fasel. 2001. A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major. Vaccine 19:3369-3375.
52. Rico, A. I., G. Del Real, M. Soto, L. Quijada, A. C. Martinez, C. Alonso, and J. M. Requena. 1998. Characterization of the immunostimulatory properties of Leishmania infantum HSP70 by fusion to the Escherichia coli maltose-binding protein in normal and nu/nu BALB/c mice. Infect. Immun. 66:347-352.
53. Sacks, D. L., S. Hieny, and A. Sher. 1985. Identification of cell surface carbohydrate and antigenic changes between noninfective and infective developmental stages of Leishmania major promastigotes. J. Immunol. 135:564-569.
54. Serezani, C. H., A. R. Franco, M. Wajc, J. K. Umada Yokoyama-Yasunaka, G. Wunderlich, M. M. Borges, and S. R. Uliana. 2002. Evaluation of the murine immune response to Leishmania meta 1 antigen delivered as recombinant protein or DNA vaccine. Vaccine 20:3755-3763.
55. Sharifi, I., A. R. FeKri, M. R. Aflatonian, A. Khamesipour, A. Nadim, M. R. Mousavi, A. Z. Momeni, Y. Dowlati, T. Godal, F. Zicker, P. G. Smith, and F. Modabber. 1998. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet 351:1540-1543.
56. Sjolander, A., T. M. Baldwin, J. M. Curtis, K. L. Bengtsson, and E. Handman. 1998. Vaccination with recombinant parasite surface antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection. Vaccine 16:2077-2084.
57. Sjolander, A., T. M. Baldwin, J. M. Curtis, and E. Handman. 1998. Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response are required for generation of immunity to leishmaniasis. J. Immunol. 160:3949-3957.
58. Soong, L., C. H. Chang, J. Sun, B. J. Longley, Jr., N. H. Ruddle, R. A. Flavell, and D. McMahon-Pratt. 1997. Role of CD4+ T cells in pathogenesis associated with Leishmania amazonensis infection. J. Immunol. 158:5374-5383.
59. Soong, L., S. M. Duboise, P. Kima, and D. McMahon-Pratt. 1995. Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis. Infect. Immun. 63:3559-3566.
60. Stevens, T. L., A. Bossie, V. M. Sanders, R. Fernandez-Botran, R. L. Coffman, T. R. Mosmann, and E. S. Vitetta. 1988. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature 334:255-258.
61. Todoroki, I., T. Joh, K. Watanabe, M. Miyashita, K. Seno, T. Nomura, H. Ohara, Y. Yokoyama, K. Tochikubo, and M. Itoh. 2000. Suppressive effects of DNA vaccines encoding heat shock protein on Helicobacter pylori-induced gastritis in mice. Biochem. Biophys. Res. Commun. 277:159-163.
62. Ulmer, J. B., J. J. Donnelly, and M. A. Liu. 1996. DNA vaccines: promising a new approach to inducing protective immunity. ASM News 62:476.
63. Velez, I. D., S. del Pilar Agudelo, M. P. Arbelaez, K. Gilchrist, S. M. Robledo, J. A. Puerta, F. Zicker, J. Berman, and F. Modabber. 2000. Safety and immunogenicity of a killed Leishmania (L.) amazonensis vaccine against cutaneous leishmaniasis in Colombia: a randomized controlled trial. Trans. R. Soc. Trop. Med. Hyg. 94:698-703.
64. Wang, Y., C. G. Kelly, M. Singh, E. G. McGowan, A. S. Carrara, L. A. Bergmeier, and T. Lehner. 2002. Stimulation of Th1-polarizing cytokines, C-C chemokines, maturation of dendritic cells, and adjuvant function by the peptide binding fragment of heat shock protein 70. J. Immunol. 169:2422-2429.
65. World Health Organization. 1994. Leishmaniasis in the Americas. W.H.O. Rep. 15:8-11.
66. Xu, D., and F. Y. Liew. 1995. Protection against leishmaniasis by injection of DNA encoding a major surface glycoprotein, gp63, of L. major. Immunology 84:173-176.